These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9325737)

  • 21. [Experiences of 16 children treated with bone marrow transplantation (author's transl)].
    Hoshi Y; Johnson FL
    Rinsho Ketsueki; 1981 Dec; 22(12):1909-15. PubMed ID: 7047797
    [No Abstract]   [Full Text] [Related]  

  • 22. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
    Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Unrelated donor allogenetic marrow transplantation in treatment of acute and chronic leukemia].
    Huang H; Lin M; Meng H
    Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):263-7. PubMed ID: 11798883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation.
    Elmaagacli AH; Beelen DW; Trenn G; Schmidt O; Nahler M; Schaefer UW
    Bone Marrow Transplant; 1999 Apr; 23(8):771-7. PubMed ID: 10231138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Español de Trasplante Hemopoyético.
    Carreras E; Tomás JF; Sanz G; Iriondo A; Boqué C; López J; Cabrera R; Sureda A; de Soria VG; Sierra J; Sanz MA; Torres A
    Haematologica; 2000 May; 85(5):530-8. PubMed ID: 10800172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pulmonary complications occurring after allogeneic bone marrow transplantation].
    Fan Y; Guo N; Huang X
    Zhonghua Xue Ye Xue Za Zhi; 1998 Aug; 19(8):409-12. PubMed ID: 11189507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CMV-viraemia during allogenic bone marrow transplantation in paediatric patients: association with survival and graft-versus-host disease.
    Matthes-Martin S; Aberle SW; Peters C; Holter W; Popow-Kraupp T; Pötschger U; Fritsch G; Ladenstein R; Rosenmayer A; Dieckmann K; Gadner H
    Bone Marrow Transplant; 1998 Apr; 21 Suppl 2():S53-6. PubMed ID: 9630327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.
    Byrne JL; Stainer C; Cull G; Haynes AP; Bessell EM; Hale G; Waldmann H; Russell NH
    Bone Marrow Transplant; 2000 Feb; 25(4):411-7. PubMed ID: 10723585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Critical issues in bone marrow transplantation immunology.
    Perreault C; Bélanger R; Bonny Y; Gyger M; Roy DC
    Bone Marrow Transplant; 1991; 7 Suppl 1():24-5. PubMed ID: 2043881
    [No Abstract]   [Full Text] [Related]  

  • 30. Allogeneic bone marrow transplantation for leukemia.
    Butturini A; Gale RP
    Curr Opin Hematol; 1994 Nov; 1(6):402-5. PubMed ID: 9371313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
    Gadisseur AP; Gratama JW; Lamers C; van Esser JW; Bolhuis RL; Cornelissen JJ
    Bone Marrow Transplant; 1999 May; 23(10):1013-7. PubMed ID: 10373067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Contributions of acute leukaemia treatment to other fields of medicine (author's transl)].
    Rodríguez Fernández JM
    Sangre (Barc); 1981; 26(5-C):1040-5. PubMed ID: 7034242
    [No Abstract]   [Full Text] [Related]  

  • 33. Esophageal graft versus host disease.
    Sodhi SS; Srinivasan R; Thomas RM
    Gastrointest Endosc; 2000 Aug; 52(2):235. PubMed ID: 10922099
    [No Abstract]   [Full Text] [Related]  

  • 34. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bases of bone marrow transplantation: modalities and indications].
    García Laraña J
    Rev Clin Esp; 1999 Apr; 199 Suppl 1():14-21. PubMed ID: 10422446
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of leukemic relapse following unrelated umbilical cord blood transplantation with interleukin-2: potential for augmenting graft-versus-leukemia and graft-versus-host effects with cytokines.
    Goldberg SL; Pecora AL; Rosenbluth RJ; Jennis AA; Preti RA
    Bone Marrow Transplant; 2000 Aug; 26(3):353-5. PubMed ID: 10967580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
    Pavletic SZ; Smith LM; Bishop MR; Lynch JC; Tarantolo SR; Vose JM; Bierman PJ; Hadi A; Armitage JO; Kessinger A
    Am J Hematol; 2005 Apr; 78(4):265-74. PubMed ID: 15795914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia.
    Kodera Y; Morishima Y; Kato S; Akiyama Y; Sao H; Matsuyama T; Kawa K; Sakamaki H; Nakagawa S; Hirabayashi N; Dohi H; Okamoto S; Hiraoka A; Gondo H; Tsuchida M; O H; Harada M; Asano S; Juji T; Sasazuki T; Takaku F
    Bone Marrow Transplant; 1999 Nov; 24(9):995-1003. PubMed ID: 10556959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.